首页 > 最新文献

World Journal of Gastrointestinal Pharmacology and Therapeutics最新文献

英文 中文
Faecal incontinence and health related quality of life in inflammatory bowel disease patients: Findings from a tertiary care center in South Asia. 炎症性肠病患者的大便失禁和健康相关的生活质量:来自南亚三级保健中心的研究结果
Pub Date : 2016-08-06 DOI: 10.4292/wjgpt.v7.i3.447
Duminda Subasinghe, Navarathna Mudiyanselage Meththananda Navarathna, Dharmabandhu Nandadeva Samarasekera
AIMTo analyze the frequency and severity of faecal incontinence (FI) and its effect on the quality of life (QOL) in inflammatory bowel disease (IBD) patients.METHODSAll patients who attended surgical and medical gastroenterology outpatient clinics in a tertiary care center with an established diagnosis of either ulcerative colitis (UC) or Crohn's disease (CD) over a period of 10 mo were included in this study. Before enrollment into the study, the patients were explained about the study and informed consent was obtained. The patients with unidentified colitis were excluded. The data on demographics, disease characteristics, FI (Vaizey score), and quality of life (IBD-Q) were collected. Data were analyzed using SPSS version 21.RESULTSThere were 184 patients (women = 101, 54.9%; UC = 153, 83.2%) with a female preponderance for UC (male/female ratio = 1:1.5) and a male preponderance for CD (male/female = 2:1). Forty-eight (26%) patients reported symptoms of FI. Among the patients with FI, 70.8% were women (n = 34) and 29.2% were men (n = 14) with an average age of 52.7 years (range, 20-78 years). Average age of onset of FI was 48.6 (range, 22-74) years. Ten percent (n = 5) reported regular FI. Incontinence to flatus was seen in 33.3% (n = 16), to liquid faeces in 56.2% (n = 27), to solid faeces in 6.2% (n = 3) and to all three in 4.1% (n = 2). Twenty-one percent (n = 10) complained of disruption of their physical and social activity. There was no association between FI and type of IBD. Significant associations were found between FI and age (P = 0.005) and gender (P < 0.001). QOL in our cohort of patients was significantly affected by FI.CONCLUSIONIn our study, nearly a quarter of patients reported FI. There was a significant correlation between FI and QOL. Therefore, enquiring about FI in IBD patients can lead to identification of this debilitating condition. This will enable early referral for continence care in this group of patients.
目的:分析炎症性肠病(IBD)患者大便失禁(FI)的发生频率、严重程度及其对生活质量的影响。方法:所有确诊为溃疡性结肠炎(UC)或克罗恩病(CD)的三级保健中心外科和内科胃肠病学门诊10个月以上的患者纳入本研究。在入组前,向患者解释研究内容并获得知情同意。排除不明结肠炎患者。收集人口统计学、疾病特征、FI (Vaizey评分)和生活质量(IBD-Q)数据。数据采用SPSS version 21进行分析。结果:184例患者(女性101例,占54.9%;UC = 153, 83.2%),其中UC以女性为主(男女比例为1:1.5),CD以男性为主(男女比例为2:1)。48例(26%)患者报告FI症状。FI患者中,70.8%为女性(n = 34), 29.2%为男性(n = 14),平均年龄52.7岁(范围20-78岁)。FI的平均发病年龄为48.6岁(22-74岁)。10% (n = 5)报告有规律的FI。排便失禁占33.3% (n = 16),排便失禁占56.2% (n = 27),排便失禁占6.2% (n = 3),排便失禁占4.1% (n = 2)。21% (n = 10)的患者抱怨身体和社交活动受到干扰。FI与IBD类型无相关性。FI与年龄(P = 0.005)和性别(P < 0.001)有显著相关性。我们的队列患者的生活质量受到FI的显著影响。结论:在我们的研究中,近四分之一的患者报告了FI。FI与QOL有显著相关。因此,询问IBD患者的FI可以导致这种衰弱状态的识别。这将使这组患者的失禁护理早期转诊成为可能。
{"title":"Faecal incontinence and health related quality of life in inflammatory bowel disease patients: Findings from a tertiary care center in South Asia.","authors":"Duminda Subasinghe,&nbsp;Navarathna Mudiyanselage Meththananda Navarathna,&nbsp;Dharmabandhu Nandadeva Samarasekera","doi":"10.4292/wjgpt.v7.i3.447","DOIUrl":"https://doi.org/10.4292/wjgpt.v7.i3.447","url":null,"abstract":"AIM\u0000To analyze the frequency and severity of faecal incontinence (FI) and its effect on the quality of life (QOL) in inflammatory bowel disease (IBD) patients.\u0000\u0000\u0000METHODS\u0000All patients who attended surgical and medical gastroenterology outpatient clinics in a tertiary care center with an established diagnosis of either ulcerative colitis (UC) or Crohn's disease (CD) over a period of 10 mo were included in this study. Before enrollment into the study, the patients were explained about the study and informed consent was obtained. The patients with unidentified colitis were excluded. The data on demographics, disease characteristics, FI (Vaizey score), and quality of life (IBD-Q) were collected. Data were analyzed using SPSS version 21.\u0000\u0000\u0000RESULTS\u0000There were 184 patients (women = 101, 54.9%; UC = 153, 83.2%) with a female preponderance for UC (male/female ratio = 1:1.5) and a male preponderance for CD (male/female = 2:1). Forty-eight (26%) patients reported symptoms of FI. Among the patients with FI, 70.8% were women (n = 34) and 29.2% were men (n = 14) with an average age of 52.7 years (range, 20-78 years). Average age of onset of FI was 48.6 (range, 22-74) years. Ten percent (n = 5) reported regular FI. Incontinence to flatus was seen in 33.3% (n = 16), to liquid faeces in 56.2% (n = 27), to solid faeces in 6.2% (n = 3) and to all three in 4.1% (n = 2). Twenty-one percent (n = 10) complained of disruption of their physical and social activity. There was no association between FI and type of IBD. Significant associations were found between FI and age (P = 0.005) and gender (P < 0.001). QOL in our cohort of patients was significantly affected by FI.\u0000\u0000\u0000CONCLUSION\u0000In our study, nearly a quarter of patients reported FI. There was a significant correlation between FI and QOL. Therefore, enquiring about FI in IBD patients can lead to identification of this debilitating condition. This will enable early referral for continence care in this group of patients.","PeriodicalId":23755,"journal":{"name":"World Journal of Gastrointestinal Pharmacology and Therapeutics","volume":"7 3","pages":"447-52"},"PeriodicalIF":0.0,"publicationDate":"2016-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986393/pdf/WJGPT-7-447.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34423748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Incidence of leukopenia after intraperitoneal vs combined intravenous/intraperitoneal chemotherapy in pseudomyxoma peritonei. 腹膜假性粘液瘤腹腔内化疗与静脉/腹腔联合化疗后白细胞减少的发生率。
Pub Date : 2016-08-06 DOI: 10.4292/wjgpt.v7.i3.434
Philipp Horvath, Stefan Beckert, Florian Struller, Alfred Königsrainer, Ingmar Königsrainer

Aim: To investigate the clinical impact of post-hyperthermic intraperitoneal chemotherapy (HIPEC) leukopenia, intraperitoneal and combined intravenous/intraperitoneal drug administrations were compared.

Methods: Two patient cohorts were retrospectively analyzed regarding the incidence of postoperative leukopenia. The first cohort (n = 32) received Mitomycin C (MMC)-based HIPEC intraperitoneally (35 mg/m² for 90 min) and the second cohort (n = 10) received a bi-directional therapy consisting of oxaliplatin (OX) (300 mg/m(2) for 30 min) intraperitoneally and 5-fluorouracil (5-FU) 400 mg/m² plus folinic acid 20 mg/m² intravenously. The following data were collected retrospectively: Age, sex, length of operation, length of hospital stay, amount of resection including extent of peritonectomy, peritoneal cancer index, CC (completeness of cytoreduction)-status and leukocyte-count before cytoreductive surgery (CRS) and HIPEC, on days 3, 7 and 14 after CRS and HIPEC. HIPEC leukopenia was defined as < 4000 cells/m³.

Results: Leukopenia occurred statistically more often in the MMC than in the OX/5-FU-group (10/32 vs 0/10; P = 0.042). Leukopenia set-on was on day 7 after CRS and MMC-HIPEC and lasted for two to three days. Three patients (33%) required medical treatment. Patients affected by leukopenia were predominantly female (7/10 patients) and older than 50 years (8/10 patients). The length of hospital stay tended to be higher in the MMC-group without reaching statistical significance (22.5 ± 11 vs 16.5 ± 3.5 d). Length of operation (08:54 ± 01:44 vs 09:48 ± 02:28 h) were comparable between patients with and without postoperative leukopenia. Prior history of systemic chemotherapy did not trigger post-HIPEC leukopenia. Occurrence of leucopenia did not trigger surgical site infections, intraabdominal abscess formations, hospital-acquired pneumonia or anastomotic insufficiencies.

Conclusion: Surgeons must be aware that there is a higher incidence of postoperative leukopenia in MMC-based HIPEC protocols primarily affecting females and older patients.

目的:探讨高热腹腔化疗(HIPEC)后白细胞减少的临床影响,比较腹腔内给药与静脉/腹腔联合给药两种给药方式。方法:回顾性分析两组患者术后白细胞减少的发生率。第一组(n = 32)接受基于丝裂霉素C (MMC)的HIPEC腹腔注射(35 mg/m²,持续90分钟),第二组(n = 10)接受奥沙利铂(300 mg/m²,持续30分钟)腹腔注射和5-氟尿嘧啶(5-FU) 400 mg/m²加亚叶酸20 mg/m²静脉注射的双向治疗。回顾性收集以下资料:年龄、性别、手术时间、住院时间、切除量(包括腹膜切除范围)、腹膜癌指数、细胞减少完整性(CC)状态和白细胞计数,分别在细胞减少手术(CRS)和HIPEC前、CRS和HIPEC后第3、7和14天。HIPEC白细胞减少定义为< 4000细胞/m³。结果:白细胞减少在MMC组的发生率高于OX/5- fu组(10/32 vs 0/10;P = 0.042)。白细胞减少发生在CRS和MMC-HIPEC后第7天,持续2 ~ 3 d。3名患者(33%)需要治疗。白细胞减少患者以女性为主(7/10),年龄大于50岁(8/10)。mmc组住院时间更长,但无统计学意义(22.5±11 d vs 16.5±3.5 d)。术后白细胞减少患者的手术时间(08:54±01:44 h vs 09:48±02:28 h)具有可比性。既往全身性化疗史未引起hipec后白细胞减少。白细胞减少不会引起手术部位感染、腹内脓肿形成、医院获得性肺炎或吻合口功能不全。结论:外科医生必须意识到,基于mmc的HIPEC方案中,术后白细胞减少的发生率较高,主要影响女性和老年患者。
{"title":"Incidence of leukopenia after intraperitoneal vs combined intravenous/intraperitoneal chemotherapy in pseudomyxoma peritonei.","authors":"Philipp Horvath,&nbsp;Stefan Beckert,&nbsp;Florian Struller,&nbsp;Alfred Königsrainer,&nbsp;Ingmar Königsrainer","doi":"10.4292/wjgpt.v7.i3.434","DOIUrl":"https://doi.org/10.4292/wjgpt.v7.i3.434","url":null,"abstract":"<p><strong>Aim: </strong>To investigate the clinical impact of post-hyperthermic intraperitoneal chemotherapy (HIPEC) leukopenia, intraperitoneal and combined intravenous/intraperitoneal drug administrations were compared.</p><p><strong>Methods: </strong>Two patient cohorts were retrospectively analyzed regarding the incidence of postoperative leukopenia. The first cohort (n = 32) received Mitomycin C (MMC)-based HIPEC intraperitoneally (35 mg/m² for 90 min) and the second cohort (n = 10) received a bi-directional therapy consisting of oxaliplatin (OX) (300 mg/m(2) for 30 min) intraperitoneally and 5-fluorouracil (5-FU) 400 mg/m² plus folinic acid 20 mg/m² intravenously. The following data were collected retrospectively: Age, sex, length of operation, length of hospital stay, amount of resection including extent of peritonectomy, peritoneal cancer index, CC (completeness of cytoreduction)-status and leukocyte-count before cytoreductive surgery (CRS) and HIPEC, on days 3, 7 and 14 after CRS and HIPEC. HIPEC leukopenia was defined as < 4000 cells/m³.</p><p><strong>Results: </strong>Leukopenia occurred statistically more often in the MMC than in the OX/5-FU-group (10/32 vs 0/10; P = 0.042). Leukopenia set-on was on day 7 after CRS and MMC-HIPEC and lasted for two to three days. Three patients (33%) required medical treatment. Patients affected by leukopenia were predominantly female (7/10 patients) and older than 50 years (8/10 patients). The length of hospital stay tended to be higher in the MMC-group without reaching statistical significance (22.5 ± 11 vs 16.5 ± 3.5 d). Length of operation (08:54 ± 01:44 vs 09:48 ± 02:28 h) were comparable between patients with and without postoperative leukopenia. Prior history of systemic chemotherapy did not trigger post-HIPEC leukopenia. Occurrence of leucopenia did not trigger surgical site infections, intraabdominal abscess formations, hospital-acquired pneumonia or anastomotic insufficiencies.</p><p><strong>Conclusion: </strong>Surgeons must be aware that there is a higher incidence of postoperative leukopenia in MMC-based HIPEC protocols primarily affecting females and older patients.</p>","PeriodicalId":23755,"journal":{"name":"World Journal of Gastrointestinal Pharmacology and Therapeutics","volume":"7 3","pages":"434-9"},"PeriodicalIF":0.0,"publicationDate":"2016-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986400/pdf/WJGPT-7-434.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34423746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Therapeutic options for peritoneal metastasis arising from colorectal cancer. 结直肠癌腹膜转移的治疗选择。
Pub Date : 2016-08-06 DOI: 10.4292/wjgpt.v7.i3.343
Gabriel Glockzin, Hans J Schlitt, Pompiliu Piso
Peritoneal metastasis is a common sign of advanced tumor stage, tumor progression or tumor recurrence in patients with colorectal cancer. Due to the improvement of systemic chemotherapy, the development of targeted therapy and the introduction of additive treatment options such as cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), the therapeutic approach to peritoneal metastatic colorectal cancer (pmCRC) has changed over recent decades, and patient survival has improved. Moreover, in contrast to palliative systemic chemotherapy or best supportive care, the inclusion of CRS and HIPEC as inherent components of a multidisciplinary treatment regimen provides a therapeutic approach with curative intent. Although CRS and HIPEC are increasingly accepted as the standard of care for selected patients and have become part of numerous national and international guidelines, the individual role, optimal timing and ideal sequence of the different systemic, local and surgical treatment options remains a matter of debate. Ongoing and future randomized controlled clinical trials may help clarify the impact of the different components, allow for further improvement of patient selection and support the standardization of oncologic treatment regimens for pmCRC. The addition of further therapeutic options such as neoadjuvant intraperitoneal chemotherapy or pressurized intraperitoneal aerosol chemotherapy, should be investigated to optimize therapeutic regimens and further improve the oncological outcome.
腹膜转移是结直肠癌患者肿瘤晚期、肿瘤进展或肿瘤复发的常见标志。由于全身化疗的改进,靶向治疗的发展以及细胞减少手术(CRS)和腹腔热化疗(HIPEC)等附加治疗选择的引入,近几十年来,腹膜转移性结直肠癌(pmCRC)的治疗方法发生了变化,患者生存率提高。此外,与姑息性全身化疗或最佳支持治疗相比,将CRS和HIPEC作为多学科治疗方案的固有组成部分提供了一种具有治疗目的的治疗方法。尽管CRS和HIPEC越来越多地被接受为特定患者的护理标准,并已成为许多国家和国际指南的一部分,但不同的全身、局部和手术治疗方案的个体作用、最佳时机和理想顺序仍然存在争议。正在进行的和未来的随机对照临床试验可能有助于澄清不同成分的影响,允许进一步改进患者选择,并支持pmCRC肿瘤治疗方案的标准化。应研究增加进一步的治疗选择,如新辅助腹腔内化疗或加压腹腔内气溶胶化疗,以优化治疗方案,进一步改善肿瘤预后。
{"title":"Therapeutic options for peritoneal metastasis arising from colorectal cancer.","authors":"Gabriel Glockzin,&nbsp;Hans J Schlitt,&nbsp;Pompiliu Piso","doi":"10.4292/wjgpt.v7.i3.343","DOIUrl":"https://doi.org/10.4292/wjgpt.v7.i3.343","url":null,"abstract":"Peritoneal metastasis is a common sign of advanced tumor stage, tumor progression or tumor recurrence in patients with colorectal cancer. Due to the improvement of systemic chemotherapy, the development of targeted therapy and the introduction of additive treatment options such as cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), the therapeutic approach to peritoneal metastatic colorectal cancer (pmCRC) has changed over recent decades, and patient survival has improved. Moreover, in contrast to palliative systemic chemotherapy or best supportive care, the inclusion of CRS and HIPEC as inherent components of a multidisciplinary treatment regimen provides a therapeutic approach with curative intent. Although CRS and HIPEC are increasingly accepted as the standard of care for selected patients and have become part of numerous national and international guidelines, the individual role, optimal timing and ideal sequence of the different systemic, local and surgical treatment options remains a matter of debate. Ongoing and future randomized controlled clinical trials may help clarify the impact of the different components, allow for further improvement of patient selection and support the standardization of oncologic treatment regimens for pmCRC. The addition of further therapeutic options such as neoadjuvant intraperitoneal chemotherapy or pressurized intraperitoneal aerosol chemotherapy, should be investigated to optimize therapeutic regimens and further improve the oncological outcome.","PeriodicalId":23755,"journal":{"name":"World Journal of Gastrointestinal Pharmacology and Therapeutics","volume":"7 3","pages":"343-52"},"PeriodicalIF":0.0,"publicationDate":"2016-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986391/pdf/WJGPT-7-343.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34369864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 17
Overview of cytokines and nitric oxide involvement in immuno-pathogenesis of inflammatory bowel diseases. 细胞因子和一氧化氮在炎症性肠病免疫发病机制中的作用综述。
Pub Date : 2016-08-06 DOI: 10.4292/wjgpt.v7.i3.353
Imene Soufli, Ryma Toumi, Hayet Rafa, Chafia Touil-Boukoffa

Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis are complex disorders with undetermined etiology. Several hypotheses suggest that IBDs result from an abnormal immune response against endogenous flora and luminal antigens in genetically susceptible individuals. The dysfunction of the mucosal immune response is implicated in the pathogenesis of IBD. The balance between pro-inflammatory cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-8, and IL-17A], anti-inflammatory cytokines (IL-4 and IL-13), and immunoregulatory cytokines (IL-10 and transforming growth factors β) is disturbed. Moreover, evidence from animal and clinical studies demonstrate a positive correlation between an increased concentration of nitric oxide (NO) and the severity of the disease. Interestingly, proinflammatory cytokines are involved in the up-regulation of inducible oxide synthase (iNOS) expression in IBD. However, anti-inflammatory and immunoregulatory cytokines are responsible for the negative regulation of iNOS. A positive correlation between NO production and increased pro-inflammatory cytokine levels (TNF-α, IL-6, IL-17, IL-12, and interferon-γ) were reported in patients with IBD. This review focuses on the role of cytokines in intestinal inflammation and their relationship with NO in IBD.

炎症性肠病(IBDs),包括克罗恩病和溃疡性结肠炎是病因不明的复杂疾病。一些假说认为ibd是由易感个体对内源性菌群和肠道抗原的异常免疫反应引起的。黏膜免疫应答功能障碍与IBD的发病机制有关。促炎因子[肿瘤坏死因子(TNF)-α、白细胞介素(IL)-1β、IL-8和IL- 17a]、抗炎因子(IL-4和IL-13)和免疫调节因子(IL-10和转化生长因子β)之间的平衡被扰乱。此外,来自动物和临床研究的证据表明,一氧化氮(NO)浓度升高与疾病严重程度之间存在正相关关系。有趣的是,促炎细胞因子参与IBD诱导型氧化物合酶(iNOS)表达上调。然而,抗炎和免疫调节细胞因子负责iNOS的负调控。据报道,在IBD患者中,NO的产生与促炎细胞因子(TNF-α、IL-6、IL-17、IL-12和干扰素-γ)水平升高呈正相关。本文就细胞因子在IBD肠道炎症中的作用及其与NO的关系作一综述。
{"title":"Overview of cytokines and nitric oxide involvement in immuno-pathogenesis of inflammatory bowel diseases.","authors":"Imene Soufli,&nbsp;Ryma Toumi,&nbsp;Hayet Rafa,&nbsp;Chafia Touil-Boukoffa","doi":"10.4292/wjgpt.v7.i3.353","DOIUrl":"https://doi.org/10.4292/wjgpt.v7.i3.353","url":null,"abstract":"<p><p>Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis are complex disorders with undetermined etiology. Several hypotheses suggest that IBDs result from an abnormal immune response against endogenous flora and luminal antigens in genetically susceptible individuals. The dysfunction of the mucosal immune response is implicated in the pathogenesis of IBD. The balance between pro-inflammatory cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-8, and IL-17A], anti-inflammatory cytokines (IL-4 and IL-13), and immunoregulatory cytokines (IL-10 and transforming growth factors β) is disturbed. Moreover, evidence from animal and clinical studies demonstrate a positive correlation between an increased concentration of nitric oxide (NO) and the severity of the disease. Interestingly, proinflammatory cytokines are involved in the up-regulation of inducible oxide synthase (iNOS) expression in IBD. However, anti-inflammatory and immunoregulatory cytokines are responsible for the negative regulation of iNOS. A positive correlation between NO production and increased pro-inflammatory cytokine levels (TNF-α, IL-6, IL-17, IL-12, and interferon-γ) were reported in patients with IBD. This review focuses on the role of cytokines in intestinal inflammation and their relationship with NO in IBD. </p>","PeriodicalId":23755,"journal":{"name":"World Journal of Gastrointestinal Pharmacology and Therapeutics","volume":"7 3","pages":"353-60"},"PeriodicalIF":0.0,"publicationDate":"2016-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4292/wjgpt.v7.i3.353","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34369865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 241
Clinical significance and management of Barrett's esophagus with epithelial changes indefinite for dysplasia. Barrett食管上皮改变不确定的不典型增生的临床意义和处理。
Pub Date : 2016-08-06 DOI: 10.4292/wjgpt.v7.i3.406
Prashanthi N Thota, Gaurav Kistangari, Ashwini K Esnakula, David Hernandez Gonzalo, Xiu-Li Liu

Barrett's esophagus (BE) is defined as the extension of salmon-colored mucosa into the tubular esophagus ≥ 1 cm proximal to the gastroesophageal junction with biopsy confirmation of intestinal metaplasia. Patients with BE are at increased risk of esophageal adenocarcinoma (EAC), and undergo endoscopic surveillance biopsies to detect dysplasia or early EAC. Dysplasia in BE is classified as no dysplasia, indefinite for dysplasia (IND), low grade dysplasia (LGD) or high grade dysplasia (HGD). Biopsies are diagnosed as IND when the epithelial abnormalities are not sufficient to diagnose dysplasia or the nature of the epithelial abnormalities is uncertain due to inflammation or technical issues. Specific diagnostic criteria for IND are not well established and its clinical significance and management has not been well studied. Previous studies have focused on HGD in BE and led to changes and improvement in the management of BE with HGD and early EAC. Only recently, IND and LGD in BE have become focus of intense study. This review summarizes the definition, neoplastic risk and clinical management of BE IND.

Barrett食管(BE)定义为鲑鱼色粘膜延伸至胃食管交界处近端≥1cm的管状食管,活检证实为肠化生。BE患者患食管腺癌(EAC)的风险增加,需要进行内窥镜监测活检以检测不典型增生或早期EAC。BE的异常增生分为无异常增生、不明确的异常增生(IND)、低级别异常增生(LGD)或高级别异常增生(HGD)。当上皮异常不足以诊断不典型增生或上皮异常的性质因炎症或技术问题而不确定时,活检诊断为IND。IND的具体诊断标准尚未建立,其临床意义和治疗尚未得到很好的研究。以往的研究主要集中在BE中的HGD,并导致了HGD和早期EAC对BE管理的改变和改进。直到最近,BE中的IND和LGD才成为研究的热点。本文就BE IND的定义、肿瘤风险及临床处理进行综述。
{"title":"Clinical significance and management of Barrett's esophagus with epithelial changes indefinite for dysplasia.","authors":"Prashanthi N Thota,&nbsp;Gaurav Kistangari,&nbsp;Ashwini K Esnakula,&nbsp;David Hernandez Gonzalo,&nbsp;Xiu-Li Liu","doi":"10.4292/wjgpt.v7.i3.406","DOIUrl":"https://doi.org/10.4292/wjgpt.v7.i3.406","url":null,"abstract":"<p><p>Barrett's esophagus (BE) is defined as the extension of salmon-colored mucosa into the tubular esophagus ≥ 1 cm proximal to the gastroesophageal junction with biopsy confirmation of intestinal metaplasia. Patients with BE are at increased risk of esophageal adenocarcinoma (EAC), and undergo endoscopic surveillance biopsies to detect dysplasia or early EAC. Dysplasia in BE is classified as no dysplasia, indefinite for dysplasia (IND), low grade dysplasia (LGD) or high grade dysplasia (HGD). Biopsies are diagnosed as IND when the epithelial abnormalities are not sufficient to diagnose dysplasia or the nature of the epithelial abnormalities is uncertain due to inflammation or technical issues. Specific diagnostic criteria for IND are not well established and its clinical significance and management has not been well studied. Previous studies have focused on HGD in BE and led to changes and improvement in the management of BE with HGD and early EAC. Only recently, IND and LGD in BE have become focus of intense study. This review summarizes the definition, neoplastic risk and clinical management of BE IND. </p>","PeriodicalId":23755,"journal":{"name":"World Journal of Gastrointestinal Pharmacology and Therapeutics","volume":"7 3","pages":"406-11"},"PeriodicalIF":0.0,"publicationDate":"2016-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986389/pdf/WJGPT-7-406.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34369870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Effects of aging on the architecture of the ileocecal junction in rats. 衰老对大鼠回盲连接结构的影响。
Pub Date : 2016-08-06 DOI: 10.4292/wjgpt.v7.i3.416
Maria Cícera de Brito, Renato Paulo Chopard, Diego Pulzatto Cury, Ii Sei Watanabe, Cristina Eusébio Mendes, Patricia Castelucci

Aim: To evaluate the structural organization of the elastic and collagen fibers in the region of the ileocecal transition in 30 young and old male Wistar rats.

Methods: Histology, immunohistochemistry (IHC), transmission electron microscopy and scanning electron microscopy were employed in this study. The results demonstrated that there was a demarcation of the ileocecal region between the ileum and the cecum in both groups.

Results: The connective tissue fibers had different distribution patterns in the two groups. IHC revealed the presence of nitric oxide synthase, enteric neurons and smooth muscle fibers in the ileocecal junctions (ICJs) of both groups. Compared to the young group, the elderly group exhibited an increase in collagen type I fibers, a decrease in collagen type III fibers, a decreased linear density of oxytalan elastic fibers, and a greater linear density of elaunin and mature elastic fibers.

Conclusion: The results revealed changes in the patterns of distribution of collagen and elastic fibers that may lead to a possible decrease in ICJ functionality.

目的:观察30只老龄雄性Wistar大鼠回盲过渡区弹性纤维和胶原纤维的结构组织。方法:采用组织学、免疫组化、透射电镜、扫描电镜进行研究。结果表明,两组回肠和盲肠之间均有回盲区分界。结果:两组结缔组织纤维分布形态不同。免疫组化结果显示,两组大鼠回盲接合处(ICJs)均存在一氧化氮合酶、肠神经元和平滑肌纤维。与年轻组相比,老年组ⅰ型胶原纤维增加,ⅲ型胶原纤维减少,氧化talan弹性纤维线密度降低,elaunin和成熟弹性纤维线密度增大。结论:结果显示胶原和弹性纤维分布模式的改变可能导致ICJ功能下降。
{"title":"Effects of aging on the architecture of the ileocecal junction in rats.","authors":"Maria Cícera de Brito,&nbsp;Renato Paulo Chopard,&nbsp;Diego Pulzatto Cury,&nbsp;Ii Sei Watanabe,&nbsp;Cristina Eusébio Mendes,&nbsp;Patricia Castelucci","doi":"10.4292/wjgpt.v7.i3.416","DOIUrl":"https://doi.org/10.4292/wjgpt.v7.i3.416","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the structural organization of the elastic and collagen fibers in the region of the ileocecal transition in 30 young and old male Wistar rats.</p><p><strong>Methods: </strong>Histology, immunohistochemistry (IHC), transmission electron microscopy and scanning electron microscopy were employed in this study. The results demonstrated that there was a demarcation of the ileocecal region between the ileum and the cecum in both groups.</p><p><strong>Results: </strong>The connective tissue fibers had different distribution patterns in the two groups. IHC revealed the presence of nitric oxide synthase, enteric neurons and smooth muscle fibers in the ileocecal junctions (ICJs) of both groups. Compared to the young group, the elderly group exhibited an increase in collagen type I fibers, a decrease in collagen type III fibers, a decreased linear density of oxytalan elastic fibers, and a greater linear density of elaunin and mature elastic fibers.</p><p><strong>Conclusion: </strong>The results revealed changes in the patterns of distribution of collagen and elastic fibers that may lead to a possible decrease in ICJ functionality.</p>","PeriodicalId":23755,"journal":{"name":"World Journal of Gastrointestinal Pharmacology and Therapeutics","volume":"7 3","pages":"416-27"},"PeriodicalIF":0.0,"publicationDate":"2016-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986394/pdf/WJGPT-7-416.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34423744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Infertility in men with inflammatory bowel disease. 男性炎症性肠病的不育症。
Pub Date : 2016-08-06 DOI: 10.4292/wjgpt.v7.i3.361
Takeshi Shin, Hiroshi Okada

Inflammatory bowel disease (IBD) predominantly affects young adults. Fertility-related issues are therefore important in the management of patients with IBD. However, relatively modest attention has been paid to reproductive issues faced by men with IBD. To investigate the effects of IBD and its treatment on male fertility, we reviewed the current literature using a systematic search for published studies. A PubMed search were performed using the main search terms "IBD AND male infertility", "Crohn's disease AND male infertility", "ulcerative colitis AND male infertility". References in review articles were used if relevant. We noted that active inflammation, poor nutrition, alcohol use, smoking, medications, and surgery may cause infertility in men with IBD. In surgery such as proctocolectomy with ileal pouch-anal anastomosis, rectal incision seems to be associated with sexual dysfunction. Of the medications used for IBD, sulfasalazine reversibly reduces male fertility. No other medications appear to affect male fertility significantly, although small studies suggested some adverse effects. There are limited data on the effects of drugs for IBD on male fertility and pregnancy outcomes; however, patients should be informed of the possible effects of paternal drug exposure. This review provides information on fertility-related issues in men with IBD and discusses treatment options.

炎症性肠病(IBD)主要影响年轻人。因此,与生育有关的问题在IBD患者的管理中很重要。然而,对IBD患者面临的生殖问题的关注相对较少。为了研究IBD及其治疗对男性生育能力的影响,我们通过系统检索已发表的研究回顾了目前的文献。在PubMed上使用主要搜索词“IBD和男性不育症”、“克罗恩病和男性不育症”、“溃疡性结肠炎和男性不育症”进行搜索。如果评论文章中的参考文献相关,则使用。我们注意到活动性炎症、营养不良、饮酒、吸烟、药物治疗和手术可能导致IBD患者不孕。在直结肠切除术与回肠袋-肛门吻合术等手术中,直肠切口似乎与性功能障碍有关。在治疗IBD的药物中,柳氮磺胺吡啶可可逆地降低男性生育能力。其他药物似乎没有显著影响男性生育能力,尽管小型研究表明有一些副作用。关于IBD药物对男性生育能力和妊娠结局的影响的数据有限;然而,应告知患者父亲接触药物可能产生的影响。这篇综述提供了IBD男性生育相关问题的信息,并讨论了治疗方案。
{"title":"Infertility in men with inflammatory bowel disease.","authors":"Takeshi Shin,&nbsp;Hiroshi Okada","doi":"10.4292/wjgpt.v7.i3.361","DOIUrl":"https://doi.org/10.4292/wjgpt.v7.i3.361","url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD) predominantly affects young adults. Fertility-related issues are therefore important in the management of patients with IBD. However, relatively modest attention has been paid to reproductive issues faced by men with IBD. To investigate the effects of IBD and its treatment on male fertility, we reviewed the current literature using a systematic search for published studies. A PubMed search were performed using the main search terms \"IBD AND male infertility\", \"Crohn's disease AND male infertility\", \"ulcerative colitis AND male infertility\". References in review articles were used if relevant. We noted that active inflammation, poor nutrition, alcohol use, smoking, medications, and surgery may cause infertility in men with IBD. In surgery such as proctocolectomy with ileal pouch-anal anastomosis, rectal incision seems to be associated with sexual dysfunction. Of the medications used for IBD, sulfasalazine reversibly reduces male fertility. No other medications appear to affect male fertility significantly, although small studies suggested some adverse effects. There are limited data on the effects of drugs for IBD on male fertility and pregnancy outcomes; however, patients should be informed of the possible effects of paternal drug exposure. This review provides information on fertility-related issues in men with IBD and discusses treatment options. </p>","PeriodicalId":23755,"journal":{"name":"World Journal of Gastrointestinal Pharmacology and Therapeutics","volume":"7 3","pages":"361-9"},"PeriodicalIF":0.0,"publicationDate":"2016-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4292/wjgpt.v7.i3.361","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34369866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 35
Increase in colonic diverticular hemorrhage and confounding factors. 结肠憩室出血增加及混杂因素。
Pub Date : 2016-08-06 DOI: 10.4292/wjgpt.v7.i3.440
Ken Kinjo, Toshiyuki Matsui, Takashi Hisabe, Hiroshi Ishihara, Shinichiro Maki, Kenta Chuman, Akihiro Koga, Kensei Ohtsu, Noritaka Takatsu, Fumihito Hirai, Kenshi Yao, Masakazu Washio

Aim: To classify changes over time in causes of lower gastrointestinal bleeding (LGIB) and to identify factors associated with changes in the incidence and characteristics of diverticular hemorrhage (DH).

Methods: A total of 1803 patients underwent colonoscopy for overt LGIB at our hospital from 1995 to 2013. Patients were divided into an early group (EG, 1995-2006, n = 828) and a late group (LG, 2007-2013, n = 975), and specific diseases were compared between groups. In addition, antithrombotic drug (ATD) use and nonsteroidal anti-inflammatory drug (NSAID) use were compared between patients with and without DH.

Results: Older patients (≥ 70 years old) and those with colonic DH were more frequent in LG than in EG (P < 0.01). Patients using ATDs as well as NSAIDs, male sex, obesity (body mass index ≥ 25 kg/m(2)), smoking, alcohol drinking, and arteriosclerotic diseases were more frequent in patients with DH than in those without.

Conclusion: Incidence of colonic DH seems to increase with aging of the population, and factors involved include use of ATDs and NSAIDs, male sex, obesity, smoking, alcohol drinking, and arteriosclerotic disease. These factors are of value in handling DH patients.

目的:分类下消化道出血(LGIB)的原因随时间的变化,并确定与憩室出血(DH)的发生率和特征变化相关的因素。方法:1995 - 2013年我院1803例显性LGIB患者行结肠镜检查。将患者分为早期组(EG, 1995-2006, n = 828)和晚期组(LG, 2007-2013, n = 975),比较两组间的具体疾病情况。此外,比较了有DH和无DH患者的抗血栓药物(ATD)和非甾体抗炎药(NSAID)的使用情况。结果:老年(≥70岁)和结肠DH患者发生LG的频率高于EG (P < 0.01)。在DH患者中,使用ATDs和非甾体抗炎药、男性、肥胖(体重指数≥25 kg/m(2))、吸烟、饮酒和动脉硬化疾病的患者比非DH患者更常见。结论:结肠DH的发病率似乎随着人口的老龄化而增加,其相关因素包括ATDs和NSAIDs的使用、男性、肥胖、吸烟、饮酒和动脉硬化疾病。这些因素在处理DH患者时是有价值的。
{"title":"Increase in colonic diverticular hemorrhage and confounding factors.","authors":"Ken Kinjo,&nbsp;Toshiyuki Matsui,&nbsp;Takashi Hisabe,&nbsp;Hiroshi Ishihara,&nbsp;Shinichiro Maki,&nbsp;Kenta Chuman,&nbsp;Akihiro Koga,&nbsp;Kensei Ohtsu,&nbsp;Noritaka Takatsu,&nbsp;Fumihito Hirai,&nbsp;Kenshi Yao,&nbsp;Masakazu Washio","doi":"10.4292/wjgpt.v7.i3.440","DOIUrl":"https://doi.org/10.4292/wjgpt.v7.i3.440","url":null,"abstract":"<p><strong>Aim: </strong>To classify changes over time in causes of lower gastrointestinal bleeding (LGIB) and to identify factors associated with changes in the incidence and characteristics of diverticular hemorrhage (DH).</p><p><strong>Methods: </strong>A total of 1803 patients underwent colonoscopy for overt LGIB at our hospital from 1995 to 2013. Patients were divided into an early group (EG, 1995-2006, n = 828) and a late group (LG, 2007-2013, n = 975), and specific diseases were compared between groups. In addition, antithrombotic drug (ATD) use and nonsteroidal anti-inflammatory drug (NSAID) use were compared between patients with and without DH.</p><p><strong>Results: </strong>Older patients (≥ 70 years old) and those with colonic DH were more frequent in LG than in EG (P < 0.01). Patients using ATDs as well as NSAIDs, male sex, obesity (body mass index ≥ 25 kg/m(2)), smoking, alcohol drinking, and arteriosclerotic diseases were more frequent in patients with DH than in those without.</p><p><strong>Conclusion: </strong>Incidence of colonic DH seems to increase with aging of the population, and factors involved include use of ATDs and NSAIDs, male sex, obesity, smoking, alcohol drinking, and arteriosclerotic disease. These factors are of value in handling DH patients.</p>","PeriodicalId":23755,"journal":{"name":"World Journal of Gastrointestinal Pharmacology and Therapeutics","volume":"7 3","pages":"440-6"},"PeriodicalIF":0.0,"publicationDate":"2016-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986401/pdf/WJGPT-7-440.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34423747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 29
Management of pain in chronic pancreatitis with emphasis on exogenous pancreatic enzymes. 慢性胰腺炎疼痛的管理与外源性胰酶的重点。
Pub Date : 2016-08-06 DOI: 10.4292/wjgpt.v7.i3.370
Paul M Hobbs, William G Johnson, David Y Graham

One of the most challenging issues arising in patients with chronic pancreatitis is the management of abdominal pain. Many competing theories exist to explain pancreatic pain including ductal hypertension from strictures and stones, increased interstitial pressure from glandular fibrosis, pancreatic neuritis, and ischemia. This clinical problem is superimposed on a background of reduced enzyme secretion and altered feedback mechanisms. Throughout history, investigators have used these theories to devise methods to combat chronic pancreatic pain including: Lifestyle measures, antioxidants, analgesics, administration of exogenous pancreatic enzymes, endoscopic drainage procedures, and surgical drainage and resection procedures. While the value of each modality has been debated over the years, pancreatic enzyme therapy remains a viable option. Enzyme therapy restores active enzymes to the small bowel and targets the altered feedback mechanism that lead to increased pancreatic ductal and tissue pressures, ischemia, and pain. Here, we review the mechanisms and treatments for chronic pancreatic pain with a specific focus on pancreatic enzyme replacement therapy. We also discuss different approaches to overcoming a lack of clinical response update ideas for studies needed to improve the clinical use of pancreatic enzymes to ameliorate pancreatic pain.

慢性胰腺炎患者中最具挑战性的问题之一是腹痛的管理。存在许多相互竞争的理论来解释胰腺疼痛,包括狭窄和结石引起的导管高压,腺体纤维化引起的间质压力增加,胰腺神经炎和缺血。这种临床问题叠加在酶分泌减少和反馈机制改变的背景上。纵观历史,研究人员已经使用这些理论来设计治疗慢性胰腺疼痛的方法,包括:生活方式措施、抗氧化剂、镇痛药、外源性胰腺酶的管理、内窥镜引流手术、手术引流和切除手术。虽然每种方式的价值多年来一直存在争议,但胰酶治疗仍然是一种可行的选择。酶治疗恢复小肠的活性酶,并针对改变的反馈机制,导致胰腺导管和组织压力增加,缺血和疼痛。在这里,我们回顾了慢性胰腺疼痛的机制和治疗方法,并特别关注胰腺酶替代疗法。我们还讨论了克服缺乏临床反应的不同方法,为改善临床使用胰酶来改善胰腺疼痛的研究提供了新的思路。
{"title":"Management of pain in chronic pancreatitis with emphasis on exogenous pancreatic enzymes.","authors":"Paul M Hobbs,&nbsp;William G Johnson,&nbsp;David Y Graham","doi":"10.4292/wjgpt.v7.i3.370","DOIUrl":"https://doi.org/10.4292/wjgpt.v7.i3.370","url":null,"abstract":"<p><p>One of the most challenging issues arising in patients with chronic pancreatitis is the management of abdominal pain. Many competing theories exist to explain pancreatic pain including ductal hypertension from strictures and stones, increased interstitial pressure from glandular fibrosis, pancreatic neuritis, and ischemia. This clinical problem is superimposed on a background of reduced enzyme secretion and altered feedback mechanisms. Throughout history, investigators have used these theories to devise methods to combat chronic pancreatic pain including: Lifestyle measures, antioxidants, analgesics, administration of exogenous pancreatic enzymes, endoscopic drainage procedures, and surgical drainage and resection procedures. While the value of each modality has been debated over the years, pancreatic enzyme therapy remains a viable option. Enzyme therapy restores active enzymes to the small bowel and targets the altered feedback mechanism that lead to increased pancreatic ductal and tissue pressures, ischemia, and pain. Here, we review the mechanisms and treatments for chronic pancreatic pain with a specific focus on pancreatic enzyme replacement therapy. We also discuss different approaches to overcoming a lack of clinical response update ideas for studies needed to improve the clinical use of pancreatic enzymes to ameliorate pancreatic pain. </p>","PeriodicalId":23755,"journal":{"name":"World Journal of Gastrointestinal Pharmacology and Therapeutics","volume":"7 3","pages":"370-86"},"PeriodicalIF":0.0,"publicationDate":"2016-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986390/pdf/WJGPT-7-370.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34369867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 对炎症性肠病患者进行感染筛查和疫苗接种的最佳方法是什么?
Pub Date : 2016-08-06 DOI: 10.4292/wjgpt.v7.i3.387
Gianluca Andrisani, Alessandro Armuzzi, Manuela Marzo, Carla Felice, Daniela Pugliese, Alfredo Papa, Luisa Guidi

The use of biological agents and immunomodulators for inflammatory bowel disease (IBD) is associated with an increased risk of opportunistic infections, in particular of viral or bacterial etiology. Despite the existence of international guidelines, many gastroenterologists have not adopted routine screening and vaccination in those patients with IBD, which are candidate for biologic therapy. Available strategies to screen, diagnose and prevent bacterial and viral infections in patients with IBD prior to start biological therapy are discussed in this review.

使用生物制剂和免疫调节剂治疗炎症性肠病(IBD)与机会性感染的风险增加有关,特别是病毒或细菌病因。尽管存在国际指南,但许多胃肠病学家并未对IBD患者进行常规筛查和疫苗接种,这些患者是生物治疗的候选者。本综述讨论了在IBD患者开始生物治疗之前筛查、诊断和预防细菌和病毒感染的可用策略。
{"title":"What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?","authors":"Gianluca Andrisani,&nbsp;Alessandro Armuzzi,&nbsp;Manuela Marzo,&nbsp;Carla Felice,&nbsp;Daniela Pugliese,&nbsp;Alfredo Papa,&nbsp;Luisa Guidi","doi":"10.4292/wjgpt.v7.i3.387","DOIUrl":"https://doi.org/10.4292/wjgpt.v7.i3.387","url":null,"abstract":"<p><p>The use of biological agents and immunomodulators for inflammatory bowel disease (IBD) is associated with an increased risk of opportunistic infections, in particular of viral or bacterial etiology. Despite the existence of international guidelines, many gastroenterologists have not adopted routine screening and vaccination in those patients with IBD, which are candidate for biologic therapy. Available strategies to screen, diagnose and prevent bacterial and viral infections in patients with IBD prior to start biological therapy are discussed in this review. </p>","PeriodicalId":23755,"journal":{"name":"World Journal of Gastrointestinal Pharmacology and Therapeutics","volume":"7 3","pages":"387-96"},"PeriodicalIF":0.0,"publicationDate":"2016-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986392/pdf/WJGPT-7-387.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34369868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
期刊
World Journal of Gastrointestinal Pharmacology and Therapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1